Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Biomedica Regulatory News (OXB)

Share Price Information for Oxford Biomedica (OXB)

Share Price is delayed by 15 minutes
Get Live Data
600.00    2.00 (0.33%)
Bid:
605.00
Ask:
607.00
Spread: 2.00 (0.331%)
Market Cap: £726.22m
OXB Live PriceLast checked at - London Stock Exchange

Intraday Oxford Biomedica Share Chart

2023 AGM Notification

5 May 2023 07:00

RNS Number : 4997Y
Oxford Biomedica PLC
05 May 2023
 

Oxford Biomedica PLC

2023 AGM Notification

London, UK - 5 May 2023: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica", "the Company" or "the Group"), a quality and innovation-led viral vector CDMO, gives notice that the Notice of Annual General Meeting ("AGM") together with a copy of the 2022 Annual report and accounts are being sent to shareholders today. These documents are available on the "Investors" section of the Group's website at www.oxb.com.

In accordance with Listing rule 9.6.1, a copy of the Notice of AGM has been submitted to the Financial Conduct Authority for publication through the National Storage Mechanism and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.The Company intends to hold its AGM on Friday 23 June 2023 at the offices of Oxford Biomedica, Windrush Court, Transport Way, Oxford OX4 6LT, commencing at 3:00 p.m.

 

For further information, please contact:

 

Oxford Biomedica plc:

Natalie Walter, Company Secretary

 

Tel: +44 (0)1865 783 000

 

Notes for editors

 

Oxford Biomedica (LSE: OXB) is a quality and innovation-led viral vector CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

 

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.

 

Oxford Biomedica, a FTSE4Good constituent, is headquartered in Oxford, UK. It has locations across Oxfordshire, UK and a US-based subsidiary, Oxford Biomedica Solutions, based near Boston, MA, US. Learn more at www.oxb.com, www.oxbsolutions.com, and follow us on LinkedIn, Twitter and YouTube.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NOAUSAKROUUVRAR
Date   Source Headline
11th Mar 20164:28 pmRNSHolding(s) in Company
7th Mar 20167:00 amRNSImmune Design Collaboration and Licence Expanded
1st Mar 201611:04 amRNSTotal Voting Rights
1st Mar 20169:46 amRNSHolding(s) in Company
1st Mar 20169:44 amRNSHolding(s) in Company
1st Mar 20169:38 amRNSNotice of Preliminary Results date: 28 April 2016
29th Feb 201612:16 pmRNSDirector/PDMR Shareholding
26th Feb 20164:42 pmRNSHolding(s) in Company
25th Feb 20165:16 pmRNSDirector/PDMR Shareholding
25th Feb 20162:46 pmRNSHolding(s) in Company
25th Feb 20162:45 pmRNSDirector/PDMR Shareholding
25th Feb 20169:36 amRNSHolding(s) in Company
23rd Feb 20167:00 amRNSPlacing to raise £8.1 Million
16th Feb 201610:59 amRNSHolding(s) in Company
11th Feb 20164:40 pmRNSSecond Price Monitoring Extn
11th Feb 20164:35 pmRNSPrice Monitoring Extension
2nd Feb 20169:37 amRNSTotal Voting Rights
29th Jan 20167:00 amRNSInitiation of Second CART Programme for Novartis
13th Jan 20167:00 amRNSMHRA approval to manufacture in new facility
5th Jan 20167:00 amRNSDirectorate Change
4th Jan 20167:00 amRNSBlocklisting Interim Review
4th Jan 20167:00 amRNSTotal Voting Rights
21st Dec 20152:11 pmRNSTotal Voting Rights
15th Dec 20157:00 amRNSAppointment of New Chairman
2nd Dec 201511:14 amRNSTotal Voting Rights
30th Nov 201511:32 amRNSHolding(s) in Company
20th Nov 20154:40 pmRNSSecond Price Monitoring Extn
20th Nov 20154:35 pmRNSPrice Monitoring Extension
18th Nov 20159:43 amRNSOXB present at Jefferies Healthcare Conference
13th Nov 20154:35 pmRNSPrice Monitoring Extension
4th Nov 20157:00 amRNSBusiness Update
2nd Nov 20157:00 amRNSTotal Voting Rights
28th Oct 20157:00 amRNSGSK Exercises Option on OXB LentiVector Patents
1st Oct 20154:10 pmRNSTotal Voting Rights
11th Sep 20154:35 pmRNSPrice Monitoring Extension
2nd Sep 20153:12 pmRNSHolding(s) in Company
1st Sep 20157:03 amRNSTotal Voting Rights
27th Aug 20157:00 amRNSInterim Results
6th Aug 20155:16 pmRNSHolding(s) in Company
6th Aug 20157:00 amRNSNotice of Interim Results
3rd Aug 20157:00 amRNSTotal Voting Rights
1st Jul 20158:54 amRNSDirector/PDMR Shareholding
1st Jul 20157:00 amRNSBlocklisting Interim Review
1st Jul 20157:00 amRNSTotal Voting Rights
30th Jun 20159:13 amRNSDirector/PDMR Shareholding
25th Jun 20153:40 pmRNSOxford BioMedica Block listing Application
23rd Jun 201512:00 pmRNSOXB to present at JMP Securities
19th Jun 201510:26 amRNSDirector/PDMR Shareholding
17th Jun 20151:21 pmRNSDirector/PDMR Shareholding
16th Jun 20152:03 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.